A 65-year-old man is hospitalized for the management of a deep vein thrombosis (DVT) and started on a continuous intravenous unfractionated heparin infusion. On day 1, his platelet count is 180,000/μL. On day 6, his platelet count drops to 85,000/μL. He is otherwise asymptomatic, but physical examination reveals new, painful skin necrosis at the site of his previous subcutaneous heparin injections.
Which of the following is the most appropriate next step in the management of this patient?
The correct answer is:
B) Discontinue heparin and start an argatroban infusion
This patient is presenting with heparin-induced thrombocytopenia (HIT) type II. HIT is a life-threatening, immune-mediated reaction that typically occurs 5–10 days after the initiation of heparin. It is caused by IgG antibodies directed against the heparin-platelet factor 4 (PF4) complex. These antibodies bind to the Fc receptors on the surface of platelets, leading to two major consequences:
Platelet activation which triggers a massive release of prothrombotic microparticles, leading to a highly hypercoagulable state. This explains the skin necrosis and the risk of new venous or arterial thrombosis.
Platelet consumption because activated platelets are cleared by the reticuloendothelial system, causing a moderate thrombocytopenia (typically a 50% drop from baseline).
If HIT is suspected (high 4T score), the most critical steps are to stop all heparin products immediately and initiate anticoagulation with a non-heparin anticoagulant, such as a direct thrombin inhibitor (e.g., argatroban or bivalirudin) or fondaparinux.
Answer choice A: Discontinue heparin and start a warfarin loading dose, is incorrect. Warfarin is contraindicated in the acute phase of HIT. Because warfarin rapidly depletes protein C (a natural anticoagulant) before it depletes procoagulant factors, it can cause a transient prothrombotic state that leads to venous limb gangrene in HIT patients. Warfarin should only be started once the platelet count has recovered to >150,000/μL.
Answer choice C: Discontinue heparin and transfuse one unit of apheresis platelets, is incorrect. Platelet transfusions are generally avoided in HIT because they may exacerbate the condition by providing more substrate for the PF4-heparin-IgG complexes to activate, potentially worsening the thrombotic risk.
Answer choice D: Order a platelet factor 4 (PF4) enzyme-linked immunosorbent assay (ELISA) and continue heparin pending results, is incorrect. HIT is a clinical diagnosis. If the clinical suspicion is high, as evidenced by the 50% platelet drop and skin necrosis, heparin must be stopped immediately. You should not wait for laboratory confirmation (ELISA or the more specific serotonin release assay) before taking action.
Answer choice E: Perform a bone marrow biopsy to rule out drug-induced aplastic anemia, is incorrect. HIT is a peripheral destruction process, not a marrow production issue. A biopsy would show normal or increased megakaryocytes and would not provide the diagnosis.
Key Learning Point
Heparin-induced thrombocytopenia (HIT) is a paradoxical condition where heparin causes both low platelets and life-threatening thrombosis. The diagnosis is clinical (using the 4T Score: Thrombocytopenia, Timing, Thrombosis, and oTher causes). Management requires the immediate cessation of all heparin and the initiation of a direct thrombin inhibitor like argatroban.
